X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CIPLA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CIPLA DISHMAN PHARMA/
CIPLA
 
P/E (TTM) x 25.1 44.3 56.6% View Chart
P/BV x 3.3 3.9 86.6% View Chart
Dividend Yield % 0.7 0.3 200.0%  

Financials

 DISHMAN PHARMA   CIPLA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CIPLA
Mar-17
DISHMAN PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs374622 60.2%   
Low Rs129458 28.1%   
Sales per share (Unadj.) Rs197.8181.9 108.8%  
Earnings per share (Unadj.) Rs21.212.9 164.8%  
Cash flow per share (Unadj.) Rs34.729.3 118.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.4 214.6%  
Book value per share (Unadj.) Rs179.9155.7 115.5%  
Shares outstanding (eoy) m80.69804.51 10.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.33.0 42.8%   
Avg P/E ratio x11.942.0 28.3%  
P/CF ratio (eoy) x7.218.4 39.3%  
Price / Book Value ratio x1.43.5 40.3%  
Dividend payout %9.415.5 60.7%   
Avg Mkt Cap Rs m20,306434,516 4.7%   
No. of employees `0000.823.0 3.6%   
Total wages/salary Rs m5,35526,338 20.3%   
Avg. sales/employee Rs Th19,252.76,349.1 303.2%   
Avg. wages/employee Rs Th6,459.51,143.0 565.1%   
Avg. net profit/employee Rs Th2,064.1449.3 459.3%   
INCOME DATA
Net Sales Rs m15,961146,302 10.9%  
Other income Rs m2652,287 11.6%   
Total revenues Rs m16,226148,589 10.9%   
Gross profit Rs m4,10324,758 16.6%  
Depreciation Rs m1,09113,229 8.2%   
Interest Rs m9441,594 59.3%   
Profit before tax Rs m2,33412,222 19.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-70 -1.6%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,798 34.7%   
Profit after tax Rs m1,71110,354 16.5%  
Gross profit margin %25.716.9 151.9%  
Effective tax rate %26.714.7 181.7%   
Net profit margin %10.77.1 151.5%  
BALANCE SHEET DATA
Current assets Rs m11,01887,370 12.6%   
Current liabilities Rs m9,51733,081 28.8%   
Net working cap to sales %9.437.1 25.3%  
Current ratio x1.22.6 43.8%  
Inventory Days Days11087 127.1%  
Debtors Days Days3562 55.9%  
Net fixed assets Rs m16,304111,567 14.6%   
Share capital Rs m1611,609 10.0%   
"Free" reserves Rs m12,907123,645 10.4%   
Net worth Rs m14,516125,254 11.6%   
Long term debt Rs m4,18936,454 11.5%   
Total assets Rs m29,805209,532 14.2%  
Interest coverage x3.58.7 40.0%   
Debt to equity ratio x0.30.3 99.2%  
Sales to assets ratio x0.50.7 76.7%   
Return on assets %8.95.7 156.2%  
Return on equity %11.88.3 142.6%  
Return on capital %17.58.5 206.2%  
Exports to sales %24.834.2 72.5%   
Imports to sales %3.78.3 44.8%   
Exports (fob) Rs m3,95650,050 7.9%   
Imports (cif) Rs m59612,203 4.9%   
Fx inflow Rs m4,95251,066 9.7%   
Fx outflow Rs m69717,678 3.9%   
Net fx Rs m4,25533,388 12.7%   
CASH FLOW
From Operations Rs m2,78623,824 11.7%  
From Investments Rs m-1,529-13,127 11.6%  
From Financial Activity Rs m-941-13,239 7.1%  
Net Cashflow Rs m316-2,478 -12.8%  

Share Holding

Indian Promoters % 61.4 16.0 383.8%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.7 12.2 30.3%  
FIIs % 12.7 23.7 53.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 22.1 26.2 84.4%  
Shareholders   46,261 161,166 28.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Market at Record Highs; Strong ITC & RIL Performance & Other Top Cues to Sway the Market Today(Pre-Open)

Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services. At the closing bell last week.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - STERLING BIOTECH COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS